In contrast, with lower-dose semaglutide or lower-potency GLP-1RAs such as liraglutide and exenatide, Vutiglabridin further reduced food intake beyond the effect of GLP-1RA alone, consistent with an obesity-dependent secondary metabolic effect
Additionally, Mounjaro , one of the newer diabetes drugs, which was approved in May 2022 and has a unique dual mechanism of action (it activates the GLP-1 hormone as well as another hormone called the glucose-dependent insulinotropic polypeptide or GIP, both helping to improve blood sugar) may be even more effective than semaglutide in reducing weight
Change in body weight, body mass index (BMI), blood pressure, and blood lipid profile were evaluated in all trials
PT-141 (100 and 200 g/kg) increases the number of solicitations, an appetitive sexual behavior, by ovariectomized estrogen- and progesterone-primed female rats